Liposomes as drug vehicles have advantages, such as payload protection, tunable carrying capacity and improved biodistribution. However, due to the dysfunction of targeting moieties and payload loss during preparation, immunoliposomes have yet to be favo
B7-H3 has been identified as a promising immunotherapy target as it is highly expressed in pediatric glioblastoma and correlates with tumor progression and poor prognosis. We aim to evaluate a nanobody-based CAR-T cell therapy that binds B7-H3 with high affinity and hypothesize that anti-B7-H3...
Cancer therapy with antibodies Suman Paul Maximilian F. Konig Shibin Zhou Nature Reviews Cancer(2024) Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders Zhen Xia Qihan Jin
Preparation of Immunoliposomes by Direct Coupling of Antibodies Based on a Thioether Bond Chapter © 2018 Nanoliposomal System for Breast Cancer Therapy Chapter © 2022 Liposomes Conjugated with a Pilot Molecule Chapter © 2019 Data availability The authors declare that all data supporting the...
Grade IV astrocytoma, known as glioblastoma multiforme (GBM), is a highly lethal disease where the standard therapies of surgery, followed by radiation and chemotherapy, cannot significantly prolong the life expectancy of the patients. Tumour recurrence shows more aggressive form compared to the ...
IMMU-22. B7-H3 NANOBODY CAR-T AND SOLUBLE TREM2 GENETICALLY ENGINEERED MYELOID CELL THERAPY IN MURINE SYNGENEIC GLIOBLASTOMAdoi:10.1093/neuonc/noae064.393BACKGROUND. Myeloid immunosuppression can be a major impediment to CAR-T cell therapy for CNS tumors. Importantly, CAR-T cells are often ...
inhibitor [CPI] monotherapy; B: mNSCLC after chemotherapy [CTX] + CPI; C: mSCLC after CTX with/without CPI; D: immunotherapy-resistant m-melanoma; E: recurrent glioblastoma after 1st line CTX; F: hepatocellular carcinoma after prior sorafenib or lenvatinib with/without subsequent CPI therapy)....
Glioblastoma (GBM) is the most common primary brain tumour with an exceptionally fatal prognosis, as most of the patients die within 14 to 16 months after diagnosis, despite conventional therapy (4). One of the major challenges is the lack of reliable therapeutic biomarkers and effective therapy...